Canada High Court delivers good news to patent owners (full version)
The Supreme Court of Canada has clarified the tests for anticipation and obviousness and reaffirmed the patentability of so-called selection patents in a ruling that could amount to a major boon for Canadian pharmaceutical companies, as well as patentees in general
The judgment , authored by Justice Marshall Rothstein, upheld Canadian pharmaceutical company Sanofi-Aventis's patent for Plavix (clopidogrel bisulfate), a popular blood clot inhibitor, rejecting generic drug company Apotex's claims that the patent was invalid for anticipation, obviousness and double patenting.
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.